Truist raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $90 and keeps a Hold rating on the shares. The company’s Investor Day set a reasonable and highly achievable outlook that essentially bracketed consensus on all metrics, the analyst tells investors in a research note. With TAVR growth re-accelerating in Q3, and catalysts across TAVR and TMTT into 2026-2027, the narrative is certainly on the side of the company heading into the new year, Truist added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $92 from $90 at UBS
- Cautious Optimism for Edwards Lifesciences: Hold Rating Maintained Amid Back-End-Loaded Growth Expectations
- Edwards Lifesciences price target raised to $88 from $83 at Baird
- Edwards Lifesciences price target raised to $100 from $95 at Stifel
- Edwards Lifesciences price target raised to $89 from $84 at Canaccord